<SEC-DOCUMENT>0001213900-21-028423.txt : 20210521
<SEC-HEADER>0001213900-21-028423.hdr.sgml : 20210521
<ACCEPTANCE-DATETIME>20210521164600
ACCESSION NUMBER:		0001213900-21-028423
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210521
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210521
DATE AS OF CHANGE:		20210521

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Alpha Healthcare Acquisition Corp.
		CENTRAL INDEX KEY:			0001818382
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				851763759
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39532
		FILM NUMBER:		21949744

	BUSINESS ADDRESS:	
		STREET 1:		1177 AVENUE OF THE AMERICAS 5TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10105
		BUSINESS PHONE:		6463213444

	MAIL ADDRESS:	
		STREET 1:		1177 AVENUE OF THE AMERICAS 5TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10105
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea141496-8k_alphahealth.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 8-K&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(D) OF THE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Date of Report (Date of earliest event reported): May
21, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ALPHA HEALTHCARE ACQUISITION CORP.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>001-39532</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>85-1763759</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction<BR>
of incorporation)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer<BR>
Identification No.)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="border-bottom: Black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>1177 Avenue of the Americas,&nbsp;5th Floor</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>New York, New York</B></P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10036</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(646) 494-3296</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Registrant&rsquo;s telephone number, including area
code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Not Applicable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Former name or former address, if changed since last
report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Check the appropriate box below
if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#9746; Written communication pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#9744; Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#9744; Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#9744; Pre-commencements communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Securities registered pursuant to Section 12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Title of each
    class</B></P></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Trading Symbols</B></P></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Name of each exchange
    on which registered</B></P></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Units, each consisting of one share of Class&nbsp;A Common Stock, and one-half of one Redeemable Warrant</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AHACU</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The Nasdaq Stock Market LLC</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Class A Common Stock, par value $0.0001 per share</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AHAC</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The Nasdaq Stock Market LLC</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: #CCEEFF"><B>Redeemable Warrants,
    each whole warrant exercisable for one share of Class A</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: #CCEEFF"><B>Common Stock at an exercise
    price of $11.50</B></P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AHACW</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The Nasdaq Stock Market LLC</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 3pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 3pt">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 3pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 7.01 Regulation FD Disclosure.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">On May 21, 2021, Humacyte, Inc. (&ldquo;Humacyte&rdquo;), a clinical-stage
biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, issued a press release
announcing new findings from cross-species alveolar studies in laboratory and pre-clinical models supporting the potential to engineer
functional lung alveoli.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">On February 17, 2021 Alpha Healthcare Acquisition
Corp. (&ldquo;AHAC&rdquo;) and Humacyte announced the execution of definitive Business Combination Agreement, by and among AHAC, Hunter
Merger Sub, Inc. and Humacyte (as it may be amended, supplemented or otherwise modified from time to time, the &ldquo;Business Combination
Agreement&rdquo;). The Business Combination Agreement provides, among other things, that on the terms and subject to the conditions set
forth therein, Hunter Merger Sub, Inc. will merge with and into Humacyte, with Humacyte surviving as a wholly-owned subsidiary of the
AHAC (the &ldquo;Business Combination&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">The press release is attached as Exhibit 99.1 to this
Current Report on Form 8-K and incorporated into this Item 7.01 by reference. A copy of the Business Combination Agreement was attached
as Exhibit 2.1 to AHAC&rsquo;s Current Report on Form 8-K filed with the Securities and Exchange Commission (&ldquo;SEC&rdquo;) on February
17, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">The foregoing (including Exhibit 99.1) is being furnished
pursuant to Item 7.01 and will not be deemed to be filed for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended
(the &ldquo;Exchange Act&rdquo;), or otherwise be subject to the liabilities of that section, nor will it be deemed to be incorporated
by reference in any filing under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), or the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 8.01 Other Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">The information included under Item 7.01 above is
incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Important Information About the Merger and Where to Find It</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">A full description of the terms of the Business Combination
will be provided in the registration statement on Form S-4 (the &ldquo;S-4 Registration Statement&rdquo;) to be filed with the SEC by
AHAC, which will include a prospectus with respect to AHAC&rsquo;s securities to be issued in connection with the Business Combination
and a proxy statement with respect to the stockholder meeting of AHAC to vote on the Business Combination. AHAC urges its investors, stockholders
and other interested persons to read, when available, the preliminary proxy statement/prospectus as well as other documents filed with
the SEC because these documents will contain important information about AHAC, Humacyte and the Business Combination. After the S-4 Registration
Statement is declared effective, the definitive proxy statement/prospectus to be included in the registration statement will be mailed
to stockholders of AHAC as of a record date to be established for voting on the proposed Business Combination. Once available, stockholders
will also be able to obtain a copy of the S-4 Registration Statement, including the proxy statement/prospectus, and other documents filed
with the SEC without charge, by directing a request to: Alpha Healthcare Acquisition Corp., 1177 Avenue of the Americas, 5<SUP>th</SUP>&nbsp;Floor,
New&nbsp;York, New&nbsp;York 10036. The preliminary and definitive proxy statement/prospectus to be included in the S-4 Registration Statement,
once available, can also be obtained, without charge, at the SEC&rsquo;s website (www.sec.gov).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Participants in the Solicitation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">AHAC and Humacyte and their respective directors and
executive officers may be considered participants in the solicitation of proxies with respect to the Business Combination under the rules
of the SEC. Information about the directors and executive officers of AHAC is set forth in AHAC&rsquo;s final prospectus filed with the
SEC pursuant to Rule 424(b) of the Securities Act on September 17, 2020, and is available free of charge at the SEC&rsquo;s website at
www.sec.gov or by directing a request to: Alpha Healthcare Acquisition Corp., Attn: Secretary, 1177 Avenue of the Americas, 5<SUP>th</SUP>&nbsp;Floor,
New&nbsp;York, New&nbsp;York 10036. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the
solicitation of AHAC&rsquo;s stockholders in connection with the proposed Business Combination will be set forth in the registration statement
containing the proxy statement/prospectus for the proposed Business Combination when it is filed with the SEC. These documents can be
obtained free of charge from the sources indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Forward-Looking Statements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">This Current Report contains forward-looking statements
that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements
by the following words: &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;should,&rdquo; &ldquo;expect,&rdquo;
&ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;predict,&rdquo;
&ldquo;project,&rdquo; &ldquo;potential,&rdquo; &ldquo;continue,&rdquo; &ldquo;ongoing&rdquo; or the negative of these terms or other
comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties
and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information
expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking
statement contained in this Current Report, we caution you that these statements are based on a combination of facts and factors currently
known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this Current Report include,
but are not limited to, statements regarding the proposed Business Combination, including the timing and structure of the Business Combination,
the proceeds of the Business Combination, the initial market capitalization of the combined company following the Closing and the benefits
of the Business Combination, as well as statements about the potential attributes and benefits of Humacyte&rsquo;s product candidates
and the format and timing of Humacyte&rsquo;s product development activities and clinical trials. We cannot assure you that the forward-looking
statements in this Current Report will prove to be accurate. These forward-looking statements are subject to a number of significant risks
and uncertainties that could cause actual results to differ materially from expected results, including, among others, the ability to
complete the Business Combination due to the failure to obtain approval from AHAC&rsquo;s stockholders or satisfy other closing conditions
in the Business Combination Agreement, the occurrence of any event that could give rise to the termination of the Business Combination
Agreement, the ability to recognize the anticipated benefits of the Business Combination, the outcome of any legal proceedings that may
be instituted against AHAC or Humacyte following announcement of the proposed Business Combination and related transactions, the impact
of COVID-19 on Humacyte&rsquo;s business and/or the ability of the parties to complete the Business Combination, the ability to obtain
or maintain the listing of AHAC&rsquo;s Class A Common Stock on Nasdaq following the proposed Business Combination, costs related to the
proposed Business Combination, changes in applicable laws or regulations, the possibility that AHAC or Humacyte may be adversely affected
by other economic, business, and/or competitive factors. and other risks and uncertainties, including those to be included under the header
&ldquo;Risk Factors&rdquo; in the S-4 Registration Statement to be filed by AHAC with the SEC and those included under the header &ldquo;Risk
Factors&rdquo; in the final prospectus of AHAC related to its initial public offering. Most of these factors are outside AHAC&rsquo;s
and Humacyte&rsquo;s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the
inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these
statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time
frame, or at all. The forward-looking statements in this Current Report represent our views as of the date of this Current Report. We
anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking
statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You
should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this
Current Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>No Offer or Solicitation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">This Current Report is not a proxy statement or solicitation
of a proxy, consent or authorization with respect to any securities or in respect of the proposed Business Combination and shall not constitute
an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of securities in any state or jurisdiction
in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such
state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 9.01 Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(d) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 9%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit<BR>
Number</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea141496ex99-1_alphahealth.htm">Press Release, dated May 21, 2021</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;<B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Alpha Healthcare Acquisition Corp.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 36%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: May 21, 2021</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Rajiv Shukla</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Rajiv Shukla</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea141496ex99-1_alphahealth.htm
<DESCRIPTION>PRESS RELEASE, DATED MAY 21, 2021
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B><IMG SRC="image_001.jpg" ALT="">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center"><FONT STYLE="background-color: white"><B>Humacyte
CEO Dr. Laura Niklason Presents Advances in Whole-Lung Engineering </B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><I>Laboratory and pre-clinical models of whole-lung
engineering further inform roadmap for building a functional lung alveolus</I></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><I>Data presented for the first time at 38th Annual
Meeting of the Japanese Association for Chest Surgery</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><B>Durham, N.C. &ndash; May 21, 2021 &ndash; </B>Humacyte, Inc.,
a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today
shared new findings from cross-species alveolar studies in laboratory and pre-clinical models supporting the potential to engineer functional
lung alveoli.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">The findings demonstrate that single-cell gene expression data point
to cell-cell communication in the lung alveolus, a key finding that may help to engineer functional lung tissues in the future. Future
preclinical studies will aim to identify the interactions that are most important for critical alveolar cell functions, and to determine
the degree of functionality of these engineered lung segments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">&ldquo;These findings are encouraging, as they suggest that although
the alveolar environment is complex, there is the potential to engineer a functional lung alveolus,&rdquo; said Laura Niklason, M.D.,
Ph.D., Chief Executive Officer of Humacyte investigator. &ldquo;We now have better insight into cell-to-cell interactions within the engineered
alveolar niche &ndash; an important next step in the development of engineered lung systems.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">The findings were presented by Dr. Niklason in an oral presentation
at the 38th Annual Meeting of the Japanese Association for Chest Surgery. While some of these results have been previously published,
these recent results on alveolar engineering have been submitted for publication in a peer-reviewed journal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">Dr. Niklason continued, &ldquo;End-stage lung disease has few therapeutic
options and transplantation is severely limited by the availability of transplantable donor organs. Engineered whole lungs may have the
potential to provide lifesaving therapy for patients with end-stage lung disease, at some point in the future. These findings represent
progress toward identifying and understanding design criteria that are essential for functional success of engineered lung airsacs, or
alveoli.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">On February 17, 2021, Alpha Healthcare Acquisition Corp. (Nasdaq:
AHAC) (&ldquo;AHAC&rdquo;), a special purpose acquisition company, and Humacyte announced the execution of a definitive business combination
agreement along with a fully committed $175 million PIPE financing agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>About Humacyte<BR>
</B>Humacyte, Inc., is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and
organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular
tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte&rsquo;s initial opportunity, a portfolio of human
acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma
repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Pre-clinical development is also underway in coronary
artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte&rsquo;s
HAVs were the first product to receive the FDA&rsquo;s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation and
received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit&nbsp;www.Humacyte.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>About Alpha Healthcare Acquisition Corp.<BR>
</B>Alpha Healthcare Acquisition Corp. (ticker: AHAC) is a special purpose acquisition company formed for the purpose of effecting a business
combination with one or more businesses in the healthcare sector (&ldquo;AHAC&rdquo;). The company was founded by Mr. Rajiv Shukla who
has two decades of buyouts, investments and operations experience in the healthcare industry. Mr.&nbsp;Shukla previously served as Chairman
and Chief Executive Officer of Constellation Alpha Capital Corp., a Nasdaq-listed&nbsp;special purpose acquisition company, that merged
with DermTech, Inc (ticker: DMTK) in August&nbsp;2019. On February 17, 2021, AHAC announced a definitive agreement to merge with Humacyte,
Inc. along with a concurrent fully committed PIPE placement of $175 million of AHAC common shares at a price of $10.00 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Important Information About the Merger and Where to Find It<BR>
</B>A full description of the terms of the business combination will be provided in a registration statement on Form S-4 filed with the
SEC by AHAC that includes a prospectus with respect to the Combined Company&rsquo;s securities to be issued in connection with the business
combination and a proxy statement with respect to the shareholder meeting of AHAC to vote on the business combination. AHAC urges its
investors, shareholders and other interested persons to read, the preliminary proxy statement/ prospectus as well as other documents filed
with the SEC because these documents will contain important information about AHAC, Humacyte and the business combination.&nbsp;After
the registration statement is declared effective, the definitive proxy statement/prospectus included in the registration statement will
be mailed to shareholders of AHAC as of a record date to be established for voting on the proposed business combination. Shareholders
will also be able to obtain a copy of the Form S-4, including the proxy statement/prospectus, and other documents filed with the SEC without
charge, by directing a request to: Alpha Healthcare Acquisition Corp., Attn: Secretary, 1177 Avenue of the Americas, 5<SUP>th</SUP>&nbsp;Floor,
New&nbsp;York, New&nbsp;York 10036. The preliminary and definitive proxy statement/prospectus to be included in the registration statement,
can also be obtained, without charge, at the SEC&rsquo;s website (www.sec.gov).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Participants in the Solicitation<BR>
</B>AHAC and Humacyte and their respective directors and executive officers may be considered participants in the solicitation of proxies
with respect to the proposed business combination described in this press release under the rules of the SEC. Information about the directors
and executive officers of AHAC is set forth in AHAC&rsquo;s final prospectus filed with the SEC pursuant to Rule 424(b) of the Securities
Act of 1933, as amended (the &ldquo;Securities Act&rdquo;) on September 17, 2020, and is available free of charge at the SEC&rsquo;s website
at www.sec.gov or by directing a request to: Alpha Healthcare Acquisition Corp., Attn: Secretary, 1177 Avenue of the Americas, 5<SUP>th</SUP>&nbsp;Floor,
New&nbsp;York, New&nbsp;York 10036. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the
solicitation of the AHAC shareholders in connection with the proposed business combination will be set forth in the registration statement
containing the proxy statement/prospectus for the proposed business combination. These documents can be obtained free of charge from the
sources indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Forward-Looking Statements<BR>
</B><I>This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available.
In some cases, you can identify forward-looking statements by the following words: &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;could,&rdquo;
&ldquo;would,&rdquo; &ldquo;should,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;potential,&rdquo; &ldquo;continue,&rdquo; &ldquo;ongoing&rdquo;
or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These
statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements
to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we
have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based
on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking
statements in this press release include, but are not limited to, statements regarding</I>&nbsp;<I>the initiation, timing, progress and
results of our clinical trials; the anticipated characteristics and performance of our HAVs, our ability to successfully complete, clinical
trials for our HAVs; the anticipated benefits of our HAVs relative to existing alternatives; the commercialization of our HAVs and our
ability to manufacture at commercial scale; the implementation of our business model, strategic plans for our business; the scope of protection
we are able to establish and maintain for intellectual property rights covering our HAVs and related technology; the timing or likelihood
of regulatory filings and approvals; timing, scope and rate of reimbursement for our HAVs; our estimated available market opportunity;
the proposed business combination, including the timing and structure of the business combination, the proceeds of the business combination,
and the benefits of the business combination. We cannot assure you that the forward-looking statements in this press release will prove
to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual
results to differ materially from expected results, including, among others, the ability to complete the business combination due to the
failure to obtain approval from AHAC&rsquo;s shareholders or satisfy other closing conditions in the Business Combination Agreement, the
occurrence of any event that could give rise to the termination of the Business Combination Agreement, the ability to recognize the anticipated
benefits of the business combination, the outcome of any legal proceedings that may be instituted against AHAC or Humacyte following announcement
of the proposed business combination and related transactions, the impact of COVID-19 on Humacyte&rsquo;s business and/or the ability
of the parties to complete the business combination, the ability to obtain or maintain the listing AHAC&rsquo;s common stock on Nasdaq
following the proposed business combination, costs related to the proposed business combination, changes in applicable laws or regulations,
the possibility that Alpha Healthcare Acquisition Corp. or Humacyte may be adversely affected by other economic, business, and/or competitive
factors, and other risks and uncertainties, including those to be included under the header &ldquo;Risk Factors&rdquo; in the registration
statement on Form S-4 filed by AHAC with the SEC and those included under the header &ldquo;Risk Factors&rdquo; in the final prospectus
of AHAC related to its initial public offering. Most of these factors are outside of AHAC&rsquo;s and Humacyte&rsquo;s control and are
difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light
of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty
by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements
in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments
will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we
have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking
statements as representing our views as of any date subsequent to the date of this press release.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Non-Solicitation<BR>
</B>This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or
in respect of the proposed business combination and shall not constitute an offer to sell or a solicitation of an offer to buy any securities
nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior
to registration or qualification under the securities laws of any such state or jurisdiction. No offer of securities shall be made except
by means of a prospectus meeting the requirements of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>###</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Humacyte Investor Contacts:<BR>
</B>Dale Sander<BR>
CFO, Humacyte<BR>
dsander@humacyte.com<BR>
<BR>
Josh Rappaport<BR>
Josh.Rappaport@sternir.com<BR>
<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Humacyte Media Contacts:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Juliana Blum</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">EVP, Corporate Development</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">blum@humacyte.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Heather Anderson</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">handerson@6degreespr.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ; ) # 2(  A$! Q$!_\0
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F8;SX?:G!<)OC;RLKDC/[U?2O#]DB+M6]U !5X OIN/\ QZ@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
